|Articles|May 21, 2023

The Latest Studies, Therapeutic Developments in C difficile

New therapeutics have been FDA approved as well as real-world studies glean information about their efficacy.

Within this area of care, there are a number of ongoing studies looking at new therapies to treat and prevent Clostridioides difficile infection (CDI). In the last several months, there has also been FDA approved therapeutics to treat recurrent C diff.

Learn more about these investigational therapies as well as real-world studies for approved treatments.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Related to this article

September 23rd, 2026

Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign

A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.

October 8th, 2026

Implementation Science Could Close the Know-Do Gap, Potential Future of Research

Demonstrating a diagnostic test works is no longer enough. Clinicians and laboratories also need evidence on how to adopt it in everyday practice. Andrea Prinzi, PhD, MPH, SM(ASCP), explains how implementation science can help infectious disease and clinical microbiology teams turn evidence into routine care.

October 8th, 2026

Ebola Deaths Top 4,100 as Kenya Confirms First Imported Bundibugyo Case

Kenya reported its first imported Bundibugyo Ebola death as the Democratic Republic of Congo (DRC) outbreak surpassed 8,600 confirmed cases and 4,148 deaths, with 896 patients hospitalized in isolation. Here is a report on the latest numbers as well as vaccine and therapeutic study updates.

October 7th, 2026

FAQ: Measles

With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.

October 7th, 2026

VAX-31 Meets Primary Endpoints in Phase 3 Pneumococcal Vaccine Study

Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.

October 6th, 2026

Long-Acting Cabotegravir/Rilpivirine Superior to Daily Oral ART for HIV

Long-acting cabotegravir plus rilpivirine (Cabenuva) achieved superior viral suppression vs daily oral antiretroviral therapy at 6months in treatment-experienced people with HIV and detectable viremia in the phase 3b CROWN trial.

October 6th, 2026

From Pathogen to Infectious Disease Diagnosis: Multispecies Immunoblot Nearly Doubles Early Lyme Disease Detection

FDA-cleared single-step immunoblot tests built on recombinant antigens from multiple Borrelia species detected nearly twice as many early Lyme disease cases as standard 2-tier testing. Joseph J. Burrascano Jr, MD, offers insights into what the new tests mean for clinicians.